Y. Takakura, T. Fujita, M. Hashida, H. Maeda, H. Sezaki (1989)
Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties.Journal of pharmaceutical sciences, 78 3
T. Oda, F. Sato, H. Yamamoto, M. Akagi, H. Maeda (1989)
Cytotoxicity of smancs in comparison with other anticancer agents against various cells in culture.Anticancer research, 9 2
Matsumura (1990)
Degradation pathway of kinins in tumor ascites and inhibition by kininase inhibitors: analysis by HPLCAgents Actions, 29
Kamata (1985)
A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigsInfect. Immunol., 48
Y. Matsumura, K. Maruo, M. Kimura, Tetsurou Yamamoto, T. Konno, H. Maeda (1991)
Kinin‐generating Cascade in Advanced Cancer Patients and in vitro StudyJapanese Journal of Cancer Research : Gann, 82
S. Hirayama, F. Sato, T. Oda, H. Maeda (1986)
[Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase. Comparative study with neocarzinostatin].The Japanese journal of antibiotics, 39 3
H. Peterson, K. Appelgren (1973)
Experimental studies on the uptake and rentention of labelled proteins in a rat tumour.European journal of cancer, 9 8
Issell (1979)
ZinostatinCancer Treat. Rep., 6
L. Greenbaum, P. Grebow, M. Johnston, A. Prakash, G. Semente (1975)
Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.Cancer research, 35 3
D. Senger, Galli Sj, A. Dvorak, C. Perruzzi, Harvey Vs, H. Dvorak (1983)
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science, 219 4587
H. Maeda, Y. Matsumura, H. Kato (1988)
Purification and identification of [hydroxyprolyl3]bradykinin in ascitic fluid from a patient with gastric cancer.The Journal of biological chemistry, 263 31
A. Kobayashi, T. Oda, H. Maeda (1988)
Protein Binding of Macromolecular Anticancer Agent SMANCS: Characterization of Poly(styrene-co-maleic acid) Derivatives as an Albumin Binding LigandJournal of Bioactive and Compatible Polymers, 3
K. Ney, S. Gidwitz, S. Pizzo (1985)
Binding and endocytosis of alpha 2-macroglobulin-plasmin complexes.Biochemistry, 24 17
Maeda (1981)
Neocarzinostatin in cancer chemotherapyAnticancer Res., 1
K. Iwai, H. Maeda, T. Konno, Y. Matsumura, R. Yamashita, K. Yamasaki, S. Hirayama, Y. Miyauchi (1987)
Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver.Anticancer research, 7 3 Pt B
H. Maeda, J. Takeshita, A. Yamashita (1980)
Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin.European journal of cancer, 16 5
S. Larson (1978)
Mechanisms of localization of gallium-67 in tumors.Seminars in nuclear medicine, 8 3
J. Bartholeyns, S. Moore (1974)
Pancreatic Ribonuclease: Enzymic and Physiological Properties of a Cross-Linked DimerScience, 186
Courtice (1963)
The origin of lipoprotein in lymph
R. Feeney, J. Whitaker (1986)
Protein tailoring for food and medical uses
F. Suzuki, T. Munakata, H. Maeda (1988)
Interferon induction by SMANCS: a polymer-conjugated derivative of neocarzinostatin.Anticancer research, 8 1
M. Kimura, Y. Matsumura, Yoshimasa Miyauchi, H. Maeda (1988)
A New Tactic for the Treatment of Jaundice: An Injectable Polymer-Conjugated Bilirubin OxidaseProceedings of the Society for Experimental Biology and Medicine, 188
S. Rosenberg (1969)
LYMPH AND THE LYMPHATIC SYSTEMThe American Journal of the Medical Sciences, 258
Maeda (1981)
A pharmacokinetic simulation model for chemotherapy of brain tumor with an antitumor protein antibiotic, neocarzinostatin. Theoretical considerations behind a two-compartment model for continuous infusion via an internal carotid arteryCancer Chemother. Pharmacol., 5
T. Konno, H. Maeda, K. Iwai, Shôjirô Maki, S. Tashiro, Mitsukuni Uchida, Yoshimasa Miyauchi (1984)
Selective targeting of anti‐cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast mediumCancer, 54
Fred Lembeck (1953)
5-Hydroxytryptamine in a Carcinoid TumourNature, 172
H. Maeda, T. Oda, Y. Matsumura, M. Kimura (1988)
Improvement of Pharmacological Properties of Protein-Drugs by Tailoring with Synthetic PolymersJournal of Bioactive and Compatible Polymers, 3
R. Comis, T. Griffin, V. Raso, S. Ginsberg (1979)
Pharmacokinetics of the protein antitumor antibiotic neocarzinostatin after bolus injection in humans.Cancer research, 39 3
Folkman (1987)
Angiogenic factorsScience, 235
T. Konno, H. Maeda, K. Iwai, S. Tashiro, Shôjirô Maki, T. Morinaga, M. Mochinaga, Takehisa Hiraoka, I. Yokoyama (1983)
Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report.European journal of cancer & clinical oncology, 19 8
H. Maeda, J. Takeshita (1975)
Degradation of neocarzinostatin by blood sera in vitro and its inhibition by diisopropyl fluorophosphate and n-ethylmaleimide.Gan, 66 5
M. Suzuki, K. Hori, I. Abe, S. Saito, H. Sato (1981)
A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II.Journal of the National Cancer Institute, 67 3
Y. Matsumura, M. Kimura, Tetsurou Yamamoto, H. Maeda (1988)
Involvement of the Kinin‐generating Cascade in Enhanced Vascular Permeability in Tumor TissueJapanese Journal of Cancer Research : Gann, 79
H. Maeda, Tomonori Matsumoto, T. Konno, K. Iwai, M. Ueda (1984)
Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on smancsJournal of Protein Chemistry, 3
Yang Bao (1990)
CHEMICAL MODIFICATION OF SUPEROXIDE DISMUTASEChinese Journal of Pharmaceuticals
H. Yamamoto, T. Miki, T. Oda, T. Hirano, Y. Sera, M. Akagi, H. Maeda (1990)
Reduced bone marrow toxicity of neocarzinostatin by conjugation with divinyl ether-maleic acid copolymer.European journal of cancer, 26 3
S. Maki, T. Konno, H. Maeda (1985)
Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast mediumCancer, 56
Matsumura (1988)
Involvement of kinin-generating cascade in enhanced vascular permeability in tumor tissueJpn. J. Cancer Res., 79
Suzuki (1987)
Medial regression and its functional significance in tumor-supplying host arteriesCancer, 59
Y. Matsumura, H. Maeda (1986)
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.Cancer research, 46 12 Pt 1
C. Buys, Ash Dejong, J. Bouma, M. Gruber (1975)
Rapid uptake by liver sinusoidal cells of serum albumin modified with retention of its compact conformation.Biochimica et biophysica acta, 392 1
Suzuki (1981)
A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin IIJ. Natl. Cancer Inst., 67
Y. Yumoto, K. Jinno, K. Tokuyama, Y. Araki, T. Ishimitsu, H. Maeda, T. Konno, S. Iwamoto, K. Ohnishi, K. Okuda (1985)
Hepatocellular carcinoma detected by iodized oil.Radiology, 154 1
K. Iwai, H. Maeda, T. Konno (1984)
Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image.Cancer research, 44 5
M. Hashida, A. Kato, T. Kojima, S. Muranishi, H. Sezaki, N. Tanigawa, K. Satomura, Y. Hikasa (1981)
Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.Gan, 72 2
H. Maeda, Y. Matsumura (1989)
Tumoritropic and lymphotropic principles of macromolecular drugs.Critical reviews in therapeutic drug carrier systems, 6 3
S. Skinner, P. Tutton, P. O’Brien (1990)
Microvascular architecture of experimental colon tumors in the rat.Cancer research, 50 8
Y. Takakura, Y. Kaneko, T. Fujita, M. Hashida, H. Maeda, H. Sezaki (1989)
Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. I: Synthesis and characterization.Journal of pharmaceutical sciences, 78 2
Maeda (1990)
Kinin-generating cascade in cancer. Clinical and in vitro study and utilization for tumor targetingJ. Cancer Res. Clin. Oncol., 116
S. Noda, S. Konno, J. Tanaka, M. Yamada, N. Yoshitake (1990)
Treatment of renal cell carcinoma with intra-arterial administration of SMANCS dissolved in Lipiodol.Anticancer research, 10 3
B. Vargaftig, N. Hai (1972)
Selective inhibition by mepacrine of the release of “rabbit aorta contracting substance” evoked by the administration of bradykininJournal of Pharmacy and Pharmacology, 24
Shibata (1978)
Rat ?1-acid glycoprotein: uptake by inflammatory and tumor tissueBr. J. Exp. Patholol., 59
F. Suzuki, R. Pollard, S. Uchimura, T. Munakata, H. Maeda (1990)
Role of natural killer cells and macrophages in the nonspecific resistance to tumors in mice stimulated with SMANCS, a polymer-conjugated derivative of neocarzinostatin.Cancer research, 50 13
Folkman (1974)
Tumor angiogenesisAdv. Cancer Res., 19
H. Maeda, M. Ueda, T. Morinaga, T. Matsumoto (1985)
Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: pronounced improvements in pharmacological properties.Journal of medicinal chemistry, 28 4
Hirayama (1986)
Stability of high molecular weight anticancer agent SMANCS and its transfer from oil-phase to water-phase: comparative study with neocarzinostatinJpn. J. Antibiot., 39
H. Sato, A. Wakui, M. Hoshi, M. Kurihara, M. Yokoyama, H. Shimizu (1991)
[Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report)].Gan to kagaku ryoho. Cancer & chemotherapy, 18 3
Y. Kamisaki, H. Wada, T. Yagura, A. Matsushima, Y. Inada (1981)
Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.The Journal of pharmacology and experimental therapeutics, 216 2
Takakura (1987)
Disposition and tumor localization of mitomycin C-dextran conjugate in micePharmacol. Res., 4
H. Maeda, J. Takeshita, R. Kanamaru (2009)
A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic.International journal of peptide and protein research, 14 2
R. Kamata, Tetsuro Yamamoto, Koki Matsumoto, Hiroshi, '. Maeda (1985)
A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigsInfection and Immunity, 48
F. Levi‐Schaffer, A. Bernstein, A. Meshorer, R. Arnon (1982)
Reduced toxicity of daunorubicin by conjugation to dextran.Cancer treatment reports, 66 1
Sakamoto (1978)
Experimental and clinical studies on the formation of antibody to neocarzinostatin, a new protein antibioticCancer Treat Rep., 62
F. Zunino, R. Gambetta, A. Vigevani, S. Penco, C. Geroni, A. Marco (1981)
Biologic Activity of Daunorubicin Linked to Proteins via the Methylketone Side ChainTumori Journal, 67
H. Maeda, A. Molla (1989)
Pathogenic potentials of bacterial proteases.Clinica chimica acta; international journal of clinical chemistry, 185 3
T. Ogino, M. Inoue, Y. Ando, M. Awai, H. Maeda, Y. Morino (2009)
Chemical modification of superoxide dismutase. Extension of plasma half life of the enzyme through its reversible binding to the circulating albumin.International journal of peptide and protein research, 32 2
H. Maeda (1974)
Chemical and biological characterization of succinyl neocarzinostatin.The Journal of antibiotics, 27 5
H. Maeda (1981)
Neocarzinostatin in cancer chemotherapy (review).Anticancer research, 1 3
T. Oda, T. Morinaga, H. Maeda (1986)
Stimulation of Macrophage by Polyanions and Its Conjugated Proteins and Effect on Cell Membrane 1Proceedings of the Society for Experimental Biology and Medicine, 181
Masanori Suzuki, Tohru Takahashi, Toshio Sato (1987)
Medial regression and its functional significance in tumor‐supplying host arteries. A morphometric study of hepatic arteries in human livers with hepatocellular carcinomaCancer, 59
Advanced Drug Delivery Reviews – Pubmed
Published: May 24, 2001
Access the full text.
Sign up today, get DeepDyve free for 14 days.